Zacks Research Issues Pessimistic Forecast for WST Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Zacks Research reduced their Q2 2027 earnings per share estimates for West Pharmaceutical Services in a note issued to investors on Thursday, March 5th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $2.26 per share for the quarter, down from their previous estimate of $2.27. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q3 2027 earnings at $2.21 EPS.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The business had revenue of $805.00 million during the quarter, compared to analysts’ expectations of $795.70 million. During the same period last year, the firm posted $1.82 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS.

A number of other brokerages have also recently issued reports on WST. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. Barclays dropped their price objective on shares of West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating for the company in a research note on Friday, February 13th. UBS Group reissued a “buy” rating and issued a $340.00 price objective on shares of West Pharmaceutical Services in a report on Friday, February 13th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Finally, Morgan Stanley started coverage on shares of West Pharmaceutical Services in a report on Monday, December 1st. They set an “equal weight” rating and a $285.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Buy” and a consensus target price of $314.56.

West Pharmaceutical Services Stock Up 0.6%

WST stock opened at $245.92 on Monday. West Pharmaceutical Services has a fifty-two week low of $187.43 and a fifty-two week high of $322.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.02 and a quick ratio of 2.34. The stock has a market capitalization of $17.71 billion, a price-to-earnings ratio of 36.22, a PEG ratio of 2.61 and a beta of 1.17. The business’s fifty day moving average price is $253.72 and its two-hundred day moving average price is $262.25.

Hedge Funds Weigh In On West Pharmaceutical Services

Large investors have recently bought and sold shares of the company. Rockland Trust Co. raised its stake in shares of West Pharmaceutical Services by 6.5% during the third quarter. Rockland Trust Co. now owns 83,066 shares of the medical instruments supplier’s stock valued at $21,791,000 after acquiring an additional 5,087 shares during the last quarter. Truist Financial Corp grew its stake in shares of West Pharmaceutical Services by 73.7% in the third quarter. Truist Financial Corp now owns 29,107 shares of the medical instruments supplier’s stock worth $7,636,000 after purchasing an additional 12,348 shares during the last quarter. Cibc World Market Inc. increased its holdings in West Pharmaceutical Services by 300.0% in the third quarter. Cibc World Market Inc. now owns 18,586 shares of the medical instruments supplier’s stock valued at $4,876,000 after purchasing an additional 13,940 shares during the period. Asset Management One Co. Ltd. raised its position in West Pharmaceutical Services by 16.7% during the 3rd quarter. Asset Management One Co. Ltd. now owns 69,775 shares of the medical instruments supplier’s stock worth $18,304,000 after purchasing an additional 10,009 shares during the last quarter. Finally, North Growth Management Ltd. raised its position in West Pharmaceutical Services by 17.2% during the 3rd quarter. North Growth Management Ltd. now owns 34,000 shares of the medical instruments supplier’s stock worth $8,930,000 after purchasing an additional 5,000 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services declared that its Board of Directors has approved a stock buyback program on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is presently 12.96%.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong‑Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.